Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Abuse Potential
Interventions: Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cystic Fibrosis
Interventions: Oral Glutathione, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 2 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 18
States / cities: Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 15 more

Conditions: Metastatic Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more

Conditions: Osteoporosis, Postmenopausal Osteoporosis
Interventions: Placebo, BA058 80 mcg, teriparatide; Drug
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 2,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more

Conditions: Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions: Brentuximab Vedotin, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more

Conditions: CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions: abatacept, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Smoking Cessation
Interventions: Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 19 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 56
States / cities: Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more

Conditions: Hallux Abducto Valgus
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Castro Valley, California + 25 more

Conditions: Asthma, Seasonal Allergic Rhinitis
Interventions: Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID; Drug
Lead sponsor: Creighton University; Other
Eligibility: 15 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
Interventions: Valsartan 80 mg; Drug
Lead sponsor: Trinity Hypertension & Metabolic Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Carrollton, Texas

Conditions: Spinal Cord Injury
Interventions: FES-row-training, Arms-only-row training, Time Control; Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 20 Years to 40 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions: Alteplase 50 MG [Activase]; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more

Conditions: Parkinson's Disease
Interventions: AFQ056 with L-dopa, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more

Conditions: Growth Hormone Deficiency
Interventions: VRS-317; Drug
Lead sponsor: Versartis Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions: L-arginine, L-arginine Loading Dose, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 21 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions: E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster; Biological · Other
Lead sponsor: COL George Peoples, MD, FACS; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Annandale, Virginia

Conditions: PSP - Progressive Supranuclear Palsy
Interventions: LM11A-31, Matching Placebo; Drug
Lead sponsor: Adam Boxer; Other
Eligibility: 41 Years to 86 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke, Brain Ischemia
Interventions: ThermoSuit Cooling Induction, Magnesium Sulfate, tPA, Propofol, Etomidate, Neurothrombectomy; Device · Drug · Procedure
Lead sponsor: Life Recovery Systems; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: New Orleans, Louisiana • Danville, Pennsylvania • Wilkes-Barre, Pennsylvania + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 117
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more

Conditions: Depressive Disorder, Major, Inflammation
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glucose, High Blood
Interventions: White bread, Black beans whole boiled, Knife Mill pasta, Combo Flour Pasta, Cyclone Flour Pasta; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Healthy
Interventions: Ad26.RSV.preF, Fluarix, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Mt. Pleasant, South Carolina

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years and older
Enrollment: 601 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Brentuximab Vedotin for Systemic Sclerosis

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Smoking Cessation Study In Healthy Adolescent Smokers

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

VRS-317 in Adult Subjects With Growth Hormone Deficiency

Arginine Therapy for Sickle Cell Disease Pain

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

Helping Stroke Patients With ThermoSuit Cooling

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Effects of Black Bean Pasta Consumption on Biomarkers in Young Adults

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease